GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Gross Margin %

Zydus Lifesciences (BOM:532321) Gross Margin % : 66.19% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Zydus Lifesciences's Gross Profit for the three months ended in Dec. 2023 was ₹28,752 Mil. Zydus Lifesciences's Revenue for the three months ended in Dec. 2023 was ₹43,437 Mil. Therefore, Zydus Lifesciences's Gross Margin % for the quarter that ended in Dec. 2023 was 66.19%.


The historical rank and industry rank for Zydus Lifesciences's Gross Margin % or its related term are showing as below:

BOM:532321' s Gross Margin % Range Over the Past 10 Years
Min: 60.62   Med: 61.46   Max: 65.22
Current: 64.55


During the past 13 years, the highest Gross Margin % of Zydus Lifesciences was 65.22%. The lowest was 60.62%. And the median was 61.46%.

BOM:532321's Gross Margin % is ranked better than
79.05% of 988 companies
in the Drug Manufacturers industry
Industry Median: 46.48 vs BOM:532321: 64.55

Zydus Lifesciences had a gross margin of 66.19% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Zydus Lifesciences was -0.30% per year.


Zydus Lifesciences Gross Margin % Historical Data

The historical data trend for Zydus Lifesciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Gross Margin % Chart

Zydus Lifesciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.17 62.72 64.10 60.76 61.14

Zydus Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.69 59.92 66.86 65.39 66.19

Competitive Comparison of Zydus Lifesciences's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Gross Margin % falls into.



Zydus Lifesciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Zydus Lifesciences's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )=Gross Profit (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=103189 / 168778
=(Revenue - Cost of Goods Sold) / Revenue
=(168778 - 65589) / 168778
=61.14 %

Zydus Lifesciences's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=28752 / 43437
=(Revenue - Cost of Goods Sold) / Revenue
=(43437 - 14685) / 43437
=66.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Zydus Lifesciences  (BOM:532321) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Zydus Lifesciences had a gross margin of 66.19% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Zydus Lifesciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (BOM:532321) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines